Moderna, Inc. Expected to Earn Q3 2025 Earnings of $1.30 Per Share (NASDAQ:MRNA)

Moderna, Inc. (NASDAQ:MRNA) – Stock analysts at William Blair raised their Q3 2025 earnings per share estimates for shares of Moderna in a research note issued to investors on Thursday, May 2nd. William Blair analyst M. Minter now forecasts that the company will post earnings of $1.30 per share for the quarter, up from their prior forecast of $1.25. William Blair has a “Market Perform” rating on the stock. The consensus estimate for Moderna’s current full-year earnings is ($7.47) per share. William Blair also issued estimates for Moderna’s Q4 2025 earnings at $1.36 EPS, FY2026 earnings at ($0.72) EPS and FY2027 earnings at $3.16 EPS.

A number of other brokerages have also weighed in on MRNA. Royal Bank of Canada lifted their target price on shares of Moderna from $125.00 to $135.00 and gave the company an “outperform” rating in a research note on Friday, May 3rd. Canaccord Genuity Group upped their target price on Moderna from $91.00 to $106.00 and gave the stock a “hold” rating in a report on Friday, May 3rd. HSBC reissued a “reduce” rating and issued a $86.00 target price (up previously from $75.00) on shares of Moderna in a research report on Monday, February 26th. Oppenheimer lifted their price target on Moderna from $142.00 to $163.00 and gave the company an “outperform” rating in a research report on Friday, May 3rd. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a report on Thursday, May 2nd. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $126.89.

Moderna Stock Down 0.9 %

Shares of Moderna stock opened at $121.07 on Monday. The company has a current ratio of 4.03, a quick ratio of 3.91 and a debt-to-equity ratio of 0.04. Moderna has a 12-month low of $62.55 and a 12-month high of $142.79. The company has a market cap of $46.40 billion, a P/E ratio of -7.73 and a beta of 1.57. The company’s fifty day simple moving average is $106.10 and its two-hundred day simple moving average is $95.05.

Moderna (NASDAQ:MRNA) last announced its earnings results on Thursday, May 2nd. The company reported ($3.07) EPS for the quarter, beating analysts’ consensus estimates of ($3.59) by $0.52. Moderna had a negative return on equity of 20.10% and a negative net margin of 115.82%. The company had revenue of $167.00 million during the quarter, compared to the consensus estimate of $93.26 million. During the same quarter in the prior year, the company earned $0.19 earnings per share. The firm’s revenue for the quarter was down 91.0% on a year-over-year basis.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. International Assets Investment Management LLC boosted its stake in shares of Moderna by 6,528.9% in the 4th quarter. International Assets Investment Management LLC now owns 387,656 shares of the company’s stock worth $38,552,000 after buying an additional 381,808 shares during the last quarter. abrdn plc lifted its holdings in Moderna by 477.5% in the fourth quarter. abrdn plc now owns 483,574 shares of the company’s stock valued at $48,091,000 after acquiring an additional 399,843 shares during the period. Van ECK Associates Corp boosted its position in Moderna by 19.2% in the fourth quarter. Van ECK Associates Corp now owns 270,774 shares of the company’s stock worth $26,929,000 after purchasing an additional 43,646 shares during the last quarter. Invesco Ltd. grew its stake in shares of Moderna by 19.8% during the 3rd quarter. Invesco Ltd. now owns 3,126,028 shares of the company’s stock valued at $322,887,000 after purchasing an additional 517,683 shares during the period. Finally, Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD increased its position in shares of Moderna by 10.5% during the 3rd quarter. Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD now owns 32,188 shares of the company’s stock valued at $3,252,000 after purchasing an additional 3,052 shares during the last quarter. Institutional investors own 75.33% of the company’s stock.

Insider Buying and Selling at Moderna

In other news, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 13th. The shares were sold at an average price of $108.54, for a total value of $1,628,100.00. Following the transaction, the director now owns 2,131,931 shares in the company, valued at $231,399,790.74. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other Moderna news, President Stephen Hoge sold 2,388 shares of the business’s stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $94.57, for a total value of $225,833.16. Following the completion of the transaction, the president now owns 1,515,898 shares of the company’s stock, valued at approximately $143,358,473.86. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction dated Wednesday, March 13th. The shares were sold at an average price of $108.54, for a total transaction of $1,628,100.00. Following the transaction, the director now owns 2,131,931 shares in the company, valued at approximately $231,399,790.74. The disclosure for this sale can be found here. In the last ninety days, insiders sold 139,954 shares of company stock worth $14,822,576. 15.20% of the stock is owned by corporate insiders.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.